Control
Apr 28 2022 |
et al., Revista da Sociedade Brasileira de Medicina Tropical, doi:10.1590/0037-8682-0565-2022 (date from preprint) | Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) |
| 71% higher mortality (p=0.64) and 90% worse improvement (p=0.42). Open label RCT late stage hospitalized patients in Brazil showing no significant difference with IL-2 or ixekizumab treatment. Mortality was lower and recovery was greater with colchicine, without statistical significance. | ||
Jan 18 2021 |
et al., Experimental and Therapeutic Medicine, doi:10.3892/etm.2021.9658 | Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19 |
| 4% longer hospitalization (p=0.78). PSM retrospective 59 hospitalized patients with severe COVID-19 showing that recombinant human interleukin-2 (rIL-2) treatment significantly increased lymphocyte counts. There were no significant differences in C-reactive protein or IL-6 .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.